N-carbamimidoyl-3-(3-((E)-3-(diaminomethyleneamino)-2-methyl-3-oxoprop-1-enyl)phenyl)-2-methylacrylamide

ID: ALA3900457

Chembl Id: CHEMBL3900457

PubChem CID: 15860077

Max Phase: Preclinical

Molecular Formula: C16H20N6O2

Molecular Weight: 328.38

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  C/C(=C\c1cccc(/C=C(\C)C(=O)NC(=N)N)c1)C(=O)N=C(N)N

Standard InChI:  InChI=1S/C16H20N6O2/c1-9(13(23)21-15(17)18)6-11-4-3-5-12(8-11)7-10(2)14(24)22-16(19)20/h3-8H,1-2H3,(H4,17,18,21,23)(H4,19,20,22,24)/b9-6+,10-7+

Standard InChI Key:  GNWHPBNSCPRHHH-KZZDLZNXSA-N

Associated Targets(Human)

SLC9A1 Tchem Sodium/hydrogen exchanger 1 (412 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC9A3 Tclin Sodium/hydrogen exchanger 3 (483 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC9A2 Tchem Sodium/hydrogen exchanger 2 (37 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 328.38Molecular Weight (Monoisotopic): 328.1648AlogP: 0.30#Rotatable Bonds: 4
Polar Surface Area: 160.44Molecular Species: NEUTRALHBA: 3HBD: 5
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 8#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.52CX Basic pKa: 7.22CX LogP: 0.53CX LogD: 0.29
Aromatic Rings: 1Heavy Atoms: 24QED Weighted: 0.30Np Likeness Score: -0.04

References

1.  (2014)  NHE3-binding compounds and methods for inhibiting phosphate transport, 
2.  (2013)  Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders, 
3.  (2016)  Nhe3-binding compounds and methods for inhibiting phosphate transport, 

Source